Document is current
Any future updates will be listed below
-
Authors
He, Dongxu
Pan, Qiongxi
Chen, Zhen
Sun, Chunyuan
Zhang, Peng
Mao, Aiqin
Zhu, Yaodan
Li, Hongjuan
Lu, Chunxiao
Xie, Mingxu
Zhou, Yin
Shen, Daoming
Tang, Chunlei
Yang, Zhenyu
Jin, Jian
Yao, Xiaoqiang
Nilius, Bernd
-
Funding
Funding for this research was provided by:
National High‐Technology Research and Development Program (863 Program) of China (2015AA020948)
Natural Science Foundation for Distinguished Young Scholars of Jiangsu Province (BK20140004)
Fundamental Research Funds for the Central Universities (JUSRP51704A)
Fundamental Research Funds for the Central Universities (JUSRP51615B)
China NSFC (91439131)
China NSFC (81622007)
China NSFC (81572940)
China NSFC (31550006)
China NSFC (21305051)
- License Information
-
More Information
Article History
Received: 20 February 2017
Revised: 18 August 2017
Accepted: 18 August 2017
First Online: 12 September 2017
Conflict of interest
: X.M., D.H., C.T., P.Z., Z.C., and Y.F.C. have filed a patent “A compound for use in increasing impaired TrpV4‐KCa2.3 interaction and its application in anti‐hypertension” to the State Intellectual Property Office of P.R. China (201710224218.9, PCT/CN2017/084079).
